Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
PRAZIQUANTEL, PYRANTEL EMBONATE
Bayer Limited
QP52AA51
PRAZIQUANTEL, PYRANTEL EMBONATE
30/345
Tablets
CAM-Companion Animal Medicine
Feline
Praziquantel, combinations
Endoparasiticide
Authorised
2009-03-20
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Big Cat Wormer Film-Coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Film-coated tablet. White to yellowish, round, biconvex tablet, unscored. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Cats. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the treatment of gastrointestinal roundworms and tapeworms: _Toxocara cati, Toxascaris leonina, Dipylidium caninum,_ _Taenia taenaeformis._ 4.3 CONTRAINDICATIONS Do not use simultaneously with piperazine compounds. Not intended for use in kittens less than 6 weeks of age. Do not use during pregnancy. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Fleas serve as intermediate hosts for one common type of tapeworm –_ Dipylidium caninum._ Tapeworm infestation is certain to re-occur unless control of intermediate hosts such as fleas, mice etc. is undertaken. As a precautionary measure to prevent the establishment of_ E. multilocularis_ in the UK or Ireland, it is recommended that all cats entering the country be treated with praziquantel. Each tablet contains: ACTIVE SUBSTANCES Pyrantel embonate 345 mg Praziquantel 30 mg EXCIPIENTS Titanium dioxide E171 (colouring agent) 2.60 mg H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _D_ _a_ _t_ _e_ _ _ _P_ _r_ _i_ _n_ _t_ _e_ _d_ _ _ _2_ _8_ _/_ _0_ _4_ _/_ _2_ _0_ _1_ _7_ _C_ _R_ _N_ _ _ _7_ _0_ _2_ _6_ _6_ _2_ _4_ _p_ _a_ _g_ _e_ _ _ _n_ _u_ _m_ _b_ _e_ _r_ _:_ _ _ _1_ 4.5 SPECIAL PRECAUTIONS Read the complete document